DE602004028731D1 - Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid - Google Patents

Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid

Info

Publication number
DE602004028731D1
DE602004028731D1 DE602004028731T DE602004028731T DE602004028731D1 DE 602004028731 D1 DE602004028731 D1 DE 602004028731D1 DE 602004028731 T DE602004028731 T DE 602004028731T DE 602004028731 T DE602004028731 T DE 602004028731T DE 602004028731 D1 DE602004028731 D1 DE 602004028731D1
Authority
DE
Germany
Prior art keywords
compositions
methods
beta amyloid
vivo
illustration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004028731T
Other languages
English (en)
Inventor
Michael Christopher Montalto
Eric Dustin Agdeppa
Tiberiu Mircea Siclovan
Amy Casey Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Electric Co
Original Assignee
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Electric Co filed Critical General Electric Co
Priority claimed from PCT/US2004/012559 external-priority patent/WO2004100998A2/en
Publication of DE602004028731D1 publication Critical patent/DE602004028731D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602004028731T 2003-05-07 2004-04-23 Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid Expired - Lifetime DE602004028731D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/431,202 US20040223912A1 (en) 2003-05-07 2003-05-07 Compositions and methods for non-invasive imaging of soluble beta-amyloid
US10/747,715 US20040223909A1 (en) 2003-05-07 2003-12-26 Compositions and methods for non-invasive imaging of soluble beta-amyloid
PCT/US2004/012559 WO2004100998A2 (en) 2003-05-07 2004-04-23 Compositions and methods for non-invasive imaging of soluble beta-amyloid

Publications (1)

Publication Number Publication Date
DE602004028731D1 true DE602004028731D1 (de) 2010-09-30

Family

ID=33416408

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004028731T Expired - Lifetime DE602004028731D1 (de) 2003-05-07 2004-04-23 Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid

Country Status (5)

Country Link
US (2) US20040223912A1 (de)
JP (1) JP4831421B2 (de)
AT (1) ATE478062T1 (de)
DE (1) DE602004028731D1 (de)
ES (1) ES2348870T3 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070054348A1 (en) * 2005-08-30 2007-03-08 Gestwicki Jason E Methods of screening bifunctional molecules for modulated pharmacokinetic properties
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
EP2808032B1 (de) 2005-12-12 2018-08-01 AC Immune S.A. A beta spezifische monoklonale antikörper mit therapeutischen eigenschaften
EP1987523B1 (de) 2006-01-26 2015-12-09 The Board Of Regents, The University Of Texas System Verfahren zur Bildgebung
MX2009000476A (es) 2006-07-14 2009-01-28 Ac Immune Sa Anticuerpo humanizado contra beta amiloide.
KR100858357B1 (ko) 2006-10-02 2008-09-11 (주) 디지탈바이오텍 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
WO2008154484A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1a inhibitors
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
US20090162280A1 (en) * 2007-12-20 2009-06-25 General Electric Company Detecting soluble a-beta
ES2544679T3 (es) 2007-12-28 2015-09-02 Prothena Biosciences Limited Tratamiento y profilaxis de la amiloidosis
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
US9801865B2 (en) * 2008-09-24 2017-10-31 The United States Of America As Represented By The Department Of Veteran Affairs Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation
US8512677B2 (en) * 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
US9198985B2 (en) 2009-05-22 2015-12-01 Vanderbuilt University Bimodal star polymer architectures as fluorescent and MRI imaging reagents
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
WO2015051159A1 (en) 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
WO2018150276A2 (en) 2017-02-16 2018-08-23 Universidad San Sebastian The combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological conditions
CN111072605B (zh) * 2019-12-17 2021-11-02 赣南医学院 一种氟烷基取代的苯并呋喃衍生物或吲哚衍生物的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560534A (en) * 1983-11-02 1985-12-24 Miles Laboratories, Inc. Polymer catalyst transducers
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US6287793B1 (en) * 1988-08-19 2001-09-11 Elan Pharmaceuticals, Inc. Diagnostic methods for alzheimer's disease
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5272055A (en) * 1991-12-24 1993-12-21 The University Of Kentucky Research Foundation Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP0721503A1 (de) * 1993-09-28 1996-07-17 The General Hospital Corporation Gebrauch von "antisense"-oligonukleotiden zur modulierung des nerven-wachstums und zum umkehren von beta/a4-induzierte morphologie
US6417178B1 (en) * 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6168776B1 (en) * 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6703407B1 (en) * 1994-09-20 2004-03-09 Eli Lilly And Company Benzofuran compounds, compositions, and methods
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
US5523309A (en) * 1995-03-10 1996-06-04 Eli Lilly And Company Benzofuran pharmaceutical compounds
AU1072897A (en) * 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
US6054114A (en) * 1996-05-08 2000-04-25 Massachusetts Institute Of Technology Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro
EP1105163A4 (de) * 1998-08-20 2003-05-02 Univ California Verfahren zur markierung amyloider plaques und neurofibrillisches gewirrs
AU2251801A (en) * 1999-12-20 2001-07-03 Eli Lilly And Company Piperidine derivatives and their use as serotonin receptor antagonists
WO2001087354A2 (en) * 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
WO2002016333A2 (en) * 2000-08-24 2002-02-28 University Of Pittsburgh Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
AUPR283801A0 (en) * 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
CA2458961C (en) * 2001-04-27 2008-07-08 The General Hospital Corporation Ocular diagnosis of alzheimer's disease

Also Published As

Publication number Publication date
JP4831421B2 (ja) 2011-12-07
ES2348870T3 (es) 2010-12-16
US20040223912A1 (en) 2004-11-11
US20040223909A1 (en) 2004-11-11
ATE478062T1 (de) 2010-09-15
JP2006528684A (ja) 2006-12-21

Similar Documents

Publication Publication Date Title
DE602004028731D1 (de) Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid
IL175667A (en) Imaging factor that includes a synthetic caspase-3 inhibitor marked with the neuroimaging agent, a radiopharmaceutical containing it, a kit for preparation of the preparation and a method for diagnosis based on it
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
MX2011010353A (es) Composicion farmaceutica.
DE60217090D1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE443260T1 (de) Kontrastmittel und verfahren zum imaging von naaldase oder psma
IS2522B (is) Mótefni fyrir ED-B-hneppi fibrónektíns, samsetningar, sem innihalda þau, og notkun þeirra til þess að sjúkdómsgreina og til þess að meðhöndla æxli og sjúkdóma, sem tengjast æðanýmyndun
ATE461449T1 (de) Verfahren zum nachweis von medizinisch relevanten zuständen in gelösten lbc-proben
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
ATE464323T1 (de) Zusammensetzungen und verfahren für die tumor- diagnose und behandlung
WO2004100998A3 (en) Compositions and methods for non-invasive imaging of soluble beta-amyloid
ATE405533T1 (de) Verfahren zur ä11cü-radiomarkierung von phenthiazin und phenothiazinartige verbindungen
ATE376428T1 (de) Metallkomplexverbindungen
JP5927634B2 (ja) 多孔質歯科ハイドロキシアパタイトを検出するためのキットおよび方法
ATE522230T1 (de) Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
DE60207612D1 (de) Verbindungen zur bilddarstellung der alzheimer-krankenheit
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
WO2009014342A3 (en) Markers and kit for diagnosis of alzheimer's disease
NZ590993A (en) Dual specificity phosphatase 1 protein (DUSP1) for diagnosis and prognosis of skin cancer
ATE320272T1 (de) Verwendung von kontrastmitteln zur herstellung eines diagnostischen mittels für die darm- lumenbildgebung